DocGo Inc.

NASDAQ:DCGO

Medical - Care Facilities

Healthcare
$0.71 -4.29%

-$0.02 today

Market cap
$70.14M
Beta
1.00
P/E (TTM)
-0.3
EPS (TTM)
-$1.90
52W Low $0.49High $1.78

Volume 1.64M

Average 0.87M

DCGO Gross Margin

Gross profit as a percentage of revenue, showing how much of each sales dollar is kept after direct costs.

DocGo Inc.NASDAQ: DCGO

Gross Margin · Q1 FY2026 · quarter ended Mar 2026

Gross margin narrows to 28.1%

Gross margin was 28.1% in Q1 FY2026, down 4.0 pp from a year earlier. On a trailing-twelve-month basis it was 29.5%, down 4.5 pp year over year. Over 3 fiscal years it narrowed by 4.5 pp.

Context

  • Gross margin widened in 1 of the last 3 fiscal years.
  • FY2025 was the lowest level in the 4 fiscal years shown.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
28.1%-4.4 pp QoQ
Last fiscal yearDec 2025
30.7%-4.0 pp YoY
LTMMar 2026
29.5%-4.5 pp YoY
Gross Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter-4.0 pp——
1 year-4.0 pp——
3 years-4.5 pp——
5 years——
10 years——

Gross Margin history

Percent of revenue · from the income statement

Latest · FY2025
30.7%
Year-over-year change
-4.0pp

Gross Margin vs competitors

How DCGO compares with its peers on the latest reported figures

  • DCGO's LTM Mar 2026 gross margin of 29.5% is the 6th highest of the 7 companies compared; the peer median is 89.5%.
  • Its year-over-year change of -4.5 pp is the lowest of 6, against a peer median of -0.5 pp.
  • Over three fiscal years its change of -4.5 pp compares with a peer median of -4.1 pp.
DCGO Competitors Peer median
Gross Margin for DCGO and competitors
Company Period LTM level YoY 3-year change
COYACoya Therapeutics, Inc.LTM Mar 202699.8% +378.1 pp—
OVIDOvid Therapeutics Inc.LTM Mar 202699.5% -0.5 pp-4.1 pp
PRLDPrelude Therapeutics IncorporatedLTM Mar 202697.7% -2.3 pp—
RCELAVITA Medical, Inc.LTM Mar 202681.4% -4.1 pp-0.3 pp
MGNXMacroGenics, Inc.LTM Mar 202669.9% +7.9 pp-24.0 pp
DCGODocGo Inc.LTM Mar 202629.5% -4.5 pp-4.5 pp
MBOTMicrobot Medical Inc.LTM Mar 2026-9.5% ——
IMMXImmix Biopharma, Inc.FY2025— ——
VANIVivani Medical, Inc.FY2025— ——
Peer median (excluding DCGO) 89.5%-0.5 pp-4.1 pp

Competitors are the stored peer set for DCGO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue318.72M440.52M624.29M616.56M322.2M
Cost of Revenue208.97M285.79M428.91M402.98M223.44M
Gross Profit109.75M154.72M195.38M213.57M98.76M
Gross Margin34.4%35.1%31.3%34.6%30.7%
Research & Development3.32M5.38M10.86M11.59M13.56M
Selling, General & Admin83.56M116.94M153.04M157.41M158.69M
Operating Expenses94.39M132.89M180.33M184.89M187.91M
Depreciation & Amortization7.51M10.57M16.43M15.88M15.66M
EBITDA28.07M33.35M32.73M45.56M(170.82M)
EBITDA Margin8.8%7.6%5.2%7.4%-53.0%
Operating Income15.36M21.83M15.05M28.69M(89.16M)
Operating Margin4.8%5.0%2.4%4.7%-27.7%
Interest Income0762.69K1.68M236.95K0
Interest Expense763.03K002.17M1.01M
Other Income / Expenses4.44M950.26K1.24M(939.72K)(98.34M)
Income Before Tax19.8M22.78M16.29M27.75M(187.5M)
Pre-Tax Margin6.2%5.2%2.6%4.5%-58.2%
Income Tax Expense615.7K(7.96M)6.24M14.39M8.87M
Net Income23.74M34.58M6.86M19.99M(182.4M)
Net Margin7.4%7.9%1.1%3.2%-56.6%
EPS (Basic)0.300.340.070.20(1.84)
EPS (Diluted)0.250.340.060.18(1.84)
Weighted Avg Shares80.29M101.23M103.51M102.4M99.07M
Weighted Avg Shares (Diluted)94.86M102.98M105.62M109.42M99.07M

DocGo Inc.

NASDAQ:DCGO

Intrinsic Alpha fair value

Locked

Current Price

$0.71

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.